JP2016526044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526044A5 JP2016526044A5 JP2016516776A JP2016516776A JP2016526044A5 JP 2016526044 A5 JP2016526044 A5 JP 2016526044A5 JP 2016516776 A JP2016516776 A JP 2016516776A JP 2016516776 A JP2016516776 A JP 2016516776A JP 2016526044 A5 JP2016526044 A5 JP 2016526044A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- seq
- acid sequence
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 229920001184 polypeptide Polymers 0.000 claims description 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 238000006467 substitution reaction Methods 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 9
- 238000012217 deletion Methods 0.000 claims 9
- 230000037430 deletion Effects 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 238000012986 modification Methods 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 3
- 102000029797 Prion Human genes 0.000 claims 3
- 108091000054 Prion Proteins 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102220276815 rs201708813 Human genes 0.000 claims 3
- 102000013498 tau Proteins Human genes 0.000 claims 3
- 108010026424 tau Proteins Proteins 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 208000018642 Semantic dementia Diseases 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 206010023497 kuru Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 208000022099 Alzheimer disease 2 Diseases 0.000 claims 1
- 102000007372 Ataxin-1 Human genes 0.000 claims 1
- 108010032963 Ataxin-1 Proteins 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 102000012192 Cystatin C Human genes 0.000 claims 1
- 108010061642 Cystatin C Proteins 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010016202 Familial Amyloidosis Diseases 0.000 claims 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000035850 clinical syndrome Diseases 0.000 claims 1
- 230000001143 conditioned effect Effects 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 1
- 201000006061 fatal familial insomnia Diseases 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000001682 neurofibril Anatomy 0.000 claims 1
- 230000001830 phrenic effect Effects 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000000463 red nucleus Anatomy 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 claims 1
- 230000009758 senescence Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828004P | 2013-05-28 | 2013-05-28 | |
| US61/828,004 | 2013-05-28 | ||
| US201361828497P | 2013-05-29 | 2013-05-29 | |
| US61/828,497 | 2013-05-29 | ||
| PCT/US2014/039760 WO2014193935A1 (en) | 2013-05-28 | 2014-05-28 | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526044A JP2016526044A (ja) | 2016-09-01 |
| JP2016526044A5 true JP2016526044A5 (enExample) | 2017-07-06 |
Family
ID=51168338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516776A Pending JP2016526044A (ja) | 2013-05-28 | 2014-05-28 | 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9988444B2 (enExample) |
| EP (1) | EP3003349B1 (enExample) |
| JP (1) | JP2016526044A (enExample) |
| KR (1) | KR20160010618A (enExample) |
| CN (1) | CN105473153A (enExample) |
| AU (1) | AU2014274253B2 (enExample) |
| CA (1) | CA2913414A1 (enExample) |
| EA (1) | EA030389B1 (enExample) |
| HK (1) | HK1223285A1 (enExample) |
| MX (1) | MX2015016263A (enExample) |
| PH (1) | PH12015502585A1 (enExample) |
| SG (1) | SG11201509647WA (enExample) |
| WO (1) | WO2014193935A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2785364B1 (en) | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
| MX358755B (es) | 2012-10-02 | 2018-09-03 | Proclara Biosciences Inc | Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides. |
| SG11201704427YA (en) * | 2014-12-03 | 2017-06-29 | Proclara Biosciences Inc | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
| CN107384960B (zh) * | 2017-07-25 | 2020-06-12 | 吉优诺（上海）基因科技有限公司 | 基于复制缺陷性重组腺病毒携带il-17结合分子转基因载体及其构建方法和应用 |
| US11692017B2 (en) | 2018-06-15 | 2023-07-04 | Amyl Therapeutics Srl | General amyloid interaction motif (GAIM) |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| BR112023001238A2 (pt) | 2020-07-24 | 2023-04-04 | Jawaharlal Nehru Centre For Advanced Scient Research | Compostos de monoimida de naftaleno e métodos para os mesmos |
| CN114057858B (zh) * | 2020-08-10 | 2023-03-21 | 上海瑞吉康生物医药有限公司 | 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽 |
| KR20250110352A (ko) | 2022-12-02 | 2025-07-18 | 알제온, 인크. | 트라미프로세이트를 이용하여 신경퇴행성 장애를 치료하는 방법 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| JP3068301B2 (ja) * | 1992-01-08 | 2000-07-24 | 三菱電機株式会社 | Ｉｃカード内のコネクタ支持固定機構 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1993024135A1 (en) | 1992-05-26 | 1993-12-09 | Immunex Corporation | Novel cytokine that binds cd30 |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| KR20030082962A (ko) | 2001-03-08 | 2003-10-23 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ) |
| DE10238846A1 (de) | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Aktive Fusionsproteine und Verfahren zu ihrer Herstellung |
| JP5096169B2 (ja) | 2005-02-01 | 2012-12-12 | ラモット・アット・テルアビブ・ユニバーシティ | アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法 |
| AU2007214399A1 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel-Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
| WO2007094003A2 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| WO2007109733A2 (en) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Diagnostic and prognostic markers and treatment strategies for multiple sclerosis |
| US20090105090A1 (en) | 2006-04-06 | 2009-04-23 | Fumiaki Uchiyama | Phage Display By Novel Filamentous Bacteriophage |
| CN101553567A (zh) | 2006-07-21 | 2009-10-07 | 台拉维夫大学拉莫特 | 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法 |
| KR101485202B1 (ko) | 2006-10-11 | 2015-01-22 | 안티토페 리미티드 | Ｔ 세포 에피토프 데이터베이스들 |
| WO2009143470A1 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| AU2009316326A1 (en) | 2008-11-24 | 2010-05-27 | Ramot At Tel-Aviv University Ltd. | Method for treating Parkinson' s disease using filamentous bacteriophage |
| WO2011084714A2 (en) * | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| JP2014509514A (ja) | 2011-03-11 | 2014-04-21 | ラモット アット テルアヴィブ ユニヴァーシティ リミテッド | 神経変性タウオパシーを治療するための方法 |
| EP2785364B1 (en) | 2011-11-29 | 2019-01-09 | Proclara Biosciences, Inc. | Use of p3 of bacteriophage as amyloid binding agents |
| MX358755B (es) * | 2012-10-02 | 2018-09-03 | Proclara Biosciences Inc | Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides. |
| SG11201704427YA (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences Inc | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal |
-
2014
- 2014-05-28 US US14/894,272 patent/US9988444B2/en active Active
- 2014-05-28 MX MX2015016263A patent/MX2015016263A/es unknown
- 2014-05-28 WO PCT/US2014/039760 patent/WO2014193935A1/en not_active Ceased
- 2014-05-28 SG SG11201509647WA patent/SG11201509647WA/en unknown
- 2014-05-28 JP JP2016516776A patent/JP2016526044A/ja active Pending
- 2014-05-28 EA EA201592272A patent/EA030389B1/ru not_active IP Right Cessation
- 2014-05-28 CN CN201480030678.2A patent/CN105473153A/zh active Pending
- 2014-05-28 HK HK16111571.6A patent/HK1223285A1/zh unknown
- 2014-05-28 AU AU2014274253A patent/AU2014274253B2/en not_active Ceased
- 2014-05-28 KR KR1020157036227A patent/KR20160010618A/ko not_active Withdrawn
- 2014-05-28 EP EP14737355.9A patent/EP3003349B1/en active Active
- 2014-05-28 CA CA2913414A patent/CA2913414A1/en not_active Abandoned
-
2015
- 2015-11-16 PH PH12015502585A patent/PH12015502585A1/en unknown
-
2018
- 2018-05-04 US US15/971,362 patent/US20180251534A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526044A5 (enExample) | ||
| US8440799B2 (en) | Methods of purifying anti A β antibodies | |
| JP6029280B2 (ja) | Ｄ−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物 | |
| JP2017538407A5 (enExample) | ||
| JP7626416B2 (ja) | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 | |
| US20210032319A1 (en) | Tau immunotherapy | |
| JP2012530055A5 (enExample) | ||
| JP2010505415A5 (enExample) | ||
| JP2014528695A5 (enExample) | ||
| RU2014118456A (ru) | Фосфоспецифичные антитела, распознающие тау | |
| CN108431044A (zh) | 抗age抗体及其使用方法 | |
| KR20180133452A (ko) | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 | |
| JP2025134876A (ja) | アミロイド沈着物を標的化するための修飾免疫グロブリン | |
| US11723951B2 (en) | Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal | |
| JP5474807B2 (ja) | 改変アミロイドβペプチド | |
| EP3003349A1 (en) | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity | |
| CN101325972B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 | |
| JP2021525074A (ja) | 構造に基づくアミロイド疾患ワクチン及び抗原のための無害な構造化足場 | |
| Patterson-Orazem | DEVELOPMENT OF CONFORMATIONAL MYOCILIN ANTIBODIES, AND BIOPHYSICAL CHARACTERIZATION OF THE MOUSE MYOCILIN OLFACTOMEDIN DOMAIN | |
| CN118525032A (zh) | 靶向白细胞介素34的化合物和方法 | |
| HK1163137A (en) | Methods of purifying anti a beta antibodies | |
| HK1117174B (en) | Methods of purifying anti a beta antibodies | |
| HK1124532B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 | |
| JP2010528583A5 (enExample) |